Cardiac imaging is an ever-evolving area, with imaging parameters and application in constant re-evaluation. This was reflected in many imaging debates and by the increased number of scientific contributions at the European Society of Cardiology Congress in 2022. While clinical trials tried to answer clinical questions related to the performance of different imaging modalities, many high-quality presentations focused on new imaging biomarkers in different scenarios, such as heart failure with preserved ejection fraction, valvular heart disease or long COVID. This highlights the need for the translation of cardiac imaging technology from research interests towards established measures of clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316344 | PMC |
| http://dx.doi.org/10.15420/ecr.2022.46 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health effects of occupational exposure to jet fuels used in the military: A systematic review of the epidemiologic literature.
Environ Int
January 2025
ICF, Reston, VA, USA. Electronic address:
Background: Jet fuels are a common chemical exposure in occupational settings involving aircraft. Jet fuels are heterogeneous mixtures of aromatic and aliphatic hydrocarbons, as well as non-hydrocarbon performance additives. Several components of jet fuels have been linked to adverse health outcomes.
View Article and Find Full Text PDFDiscontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease.
Thromb Haemost
January 2025
Hematology, Erasmus University Medical Center, Rotterdam, Netherlands.
Background: Data on risks and benefits of long-term anticoagulants in patients with a life-limiting disease are limited. This cohort study aims to describe (dis)continuation of anticoagulants and incidences of bleeding and thromboembolic events in vitamin K antagonist (VKA) users with a life-limiting disease.
Methods: Data from five Dutch anticoagulation clinics were linked to data from Statistics Netherlands and the Netherlands Cancer registry.
Inter-facility transfers to an urban level 1 trauma center and rates of secondary overtriage.
Eur J Trauma Emerg Surg
January 2025
Delray Medical Center, Division of Trauma and Critical Care Services, 5352 Linton Boulevard, Delray Beach, FL, 33484, USA.
Purpose: Many patients originally transported to non-trauma centers (NTC) require transfer to a trauma center (TC) for treatment. The aim was to analyze injury characteristics and outcomes of transfer patients and investigate the secondary overtriage (SOT).
Methods: Study included 2,056 transfers to an urban level 1 TC between 01/2016 and 06/2020.
Patients with antiphospholipid antibodies preferentially seek health information from physicians: a cross-sectional online patient quantitative survey.
Rheumatol Int
January 2025
Division of Rheumatology, Department of Medicine, University of Calgary, Cumming School of Medicine, Calgary, AB, Canada.
Little is known about how patients with antiphospholipid syndrome (APS) or antiphospholipid antibodies (aPL) access and trust health information. This research aimed to: describe the sources of information most frequently accessed/trusted by patients with APS/aPL; identify if individuals with APS/aPL perceived their health had been negatively impacted by various sources and document obstacles to accessing health information. Patients meeting Revised Sapporo Criteria for APS or with ≥1 positive aPL on ≥2 occasions were recruited to an online survey regarding their health information use at diagnosis and within 6 months preceding survey completion.
View Article and Find Full Text PDFRebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan.
Curr Oncol
January 2025
Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Douliu City 640, Taiwan.
Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This multicenter retrospective study evaluated the efficacy of first-line Afatinib and Osimertinib in NSCLC patients with EGFR 19del and no brain metastases at diagnosis.
Methods: The primary endpoints were time on treatment (ToT) and overall survival (OS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!